Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XXAGC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
dS3790a
|
|||||
| Synonyms |
DS3790a; DS3790
Click to Show/Hide
|
|||||
| Organization |
Daiichi Sankyo (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-CD37 mAb
|
Antibody Info | ||||
| Antigen Name |
Leukocyte antigen CD37 (CD37)
|
Antigen Info | ||||
| Payload Name |
DXd
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
deruxtecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific non-hodgkin lymphoma |
1 Trials
|